Form 4: AbbVie Director Thomas J. Falk Reports Acquisition of Restricted Stock Units

Director Thomas J. Falk reports acquisition of 1,203 restricted stock units and indirect ownership of 3,000 common stock shares through a limited partnership.

Summary

• On May 9, 2025, Thomas J. Falk, a director of AbbVie Inc., reported the acquisition of 1,203 restricted stock units (RSUs) under the AbbVie Amended and Restated 2013 Incentive Stock Program.
• These RSUs will be paid out in shares of AbbVie common stock on a one-to-one basis upon the earlier of the director's separation from service, death, or a change in control.
• Falk also reported indirect beneficial ownership of 3,000 shares of AbbVie common stock through a limited partnership jointly controlled with his spouse.
• He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating neutral sentiment. It simply reports transactions without expressing any positive or negative outlook.

Future Outlook

The restricted stock units will be paid out in shares of AbbVie common stock on the earlier of the director's separation from service, death, or a change in control.

Industry Context

This filing is a routine disclosure of stock ownership changes by a company insider, which is common practice for publicly traded companies like AbbVie. It provides transparency to investors regarding the holdings of key personnel.

Stakeholder Impact

• The acquisition of restricted stock units by a director aligns the director's interests with those of the shareholders, potentially encouraging decisions that benefit the company's long-term performance.

Key Dates

Keywords

AbbVie, Director, Thomas J. Falk, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, SEC, ABBV, Incentive Stock Program